awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34421542-2B01C783-C0F5-42FE-9904-5CC302CB3D17
Q34421542-2B01C783-C0F5-42FE-9904-5CC302CB3D17
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34421542-2B01C783-C0F5-42FE-9904-5CC302CB3D17
PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
P2860
Q34421542-2B01C783-C0F5-42FE-9904-5CC302CB3D17
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34421542-2B01C783-C0F5-42FE-9904-5CC302CB3D17
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1fb2955e6a7a22657cd37e73401a82707781326f
P2860
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.